Precision Biosciences Doses First Patient in FUNCTION-DMD Trial of PBGENE-DMD
Precision BioSciences, Inc. today announced the dosing of the first patient in the Phase 1/2 FUNCTION-DMD clinical trial, evaluating the safety, tolerability, and efficacy of PBGENE-DMD for the treatment of Duchenne. PBGENE-DMD is Precision’s investigational…Learn More
